Specificities of PSVD in children and transition to adulthood - Paris PSVD Meeting

Value of the Information & Strength of the Argument

The talk provides valuable insights into a rare pediatric liver disease, presenting data from a multicenter study and a French cohort. The argumentation is based on clinical and histological findings, with a clear distinction between two phenotypes. The author acknowledges limitations, such as the retrospective nature and the lack of genetic testing. The discussion on the difficulty of distinguishing the two groups histologically is particularly informative. The author’s suggestion that prothrombotic state may not play a major role in children is based on limited data but is presented as a preliminary observation. Overall, the value lies in the detailed description of pediatric PSVD and the emphasis on the need for further research.

Scientific Rigor, Source Quality, Title Accuracy

The presentation is scientifically rigorous, referencing two key studies: the French cohort (2014) and the Italian multicenter study (2022). The author is a pediatric hepatologist, lending credibility. The title accurately reflects the content. The talk is an expert opinion at a scientific meeting, not a peer-reviewed publication, but the data presented are from published studies. The author does not provide specific citations for all claims, but the context suggests they are based on the mentioned studies. The adéquation between title and content is good, as the talk focuses on pediatric-specific features and transition to adult care. No comments were provided, so no analysis of public trends is possible.

The title accurately reflects the content, focusing on pediatric-specific features of PSVD and transition to adult care.

7/10

Presentation by a pediatric hepatologist at an international scientific meeting, based on a retrospective multicenter study and a French cohort. Data are specific and detailed, but the talk is an expert opinion rather than a peer-reviewed publication, and some claims (e.g., prothrombotic state role) are based on the author's feeling.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction: PSVD in pediatric, underdiagnosis, and need for expert pediatric pathologist.
• 02:00French cohort study (2014): 48 children with OPV, clinical features, familial cases.
• 04:00Italian multicenter study: design, inclusion criteria, and histological review.
• 06:00Results: clinical phenotypes, portal hypertension vs. no portal hypertension, biopsy timing.
• 08:00Histological findings: obliterative portal venopathy, nodular regeneration, capillarization, differences between groups.
• 10:00Outcomes: survival, transplantation, vascular pulmonary complications, bleeding.
• 12:00Disease progression: children with portal hypertension progress, those without may remain stable.
• 14:00Management: portal hypertension management similar to other causes; monitoring for those without.
• 16:00Conclusion: PSVD in children has specific features, need for further studies, and genetic testing.
• 18:00Q&A: genetics not routinely used but planned.

• French cohort study on obliterative portal venopathy in children (2014) — Mentioned as the French cohort published in 2014, with 48 children, divided into four groups.
• Italian multicenter study on pediatric PSVD (2022) — The author's own study, published in 2022, with 62 children from seven centers.

• French cohort study on obliterative portal venopathy in children (2014) — The author references this study, which supports the existence of familial cases and clinical features.
• Italian multicenter study on pediatric PSVD (2022) — The author's own study, which provides the main data presented.